CHICAGO, July 6 /PRNewswire/ -- ICAP Ocean Tomo, the intellectual property brokerage division of ICAPplc (IAP.L), has been engaged to sell a patent portfolio of near-infrared spectroscopy technology owned by NIResults Inc. The portfolio includes over 90 issued US and foreign patents and patent applications. The assets have been cited by over 20 companies
The patents of this portfolio cover the use of near-infrared spectroscopy in clinical chemistry analysis systems, pulse oximeters and CO-oximeters, non-invasive glucose monitors, and hemoglobin monitors. The patents describe a method for the monitoring of key blood analytes without the need for costly, environmentally challenging, chemical reagents. The assets also include in-vitro, which is applied to a droplet of blood from a sample, and in-vivo (non-invasive) technology, which does not require a blood sample. Using near-infrared spectroscopy technology to count analytes in the blood eliminates the disadvantages associated with conventional methods such as the risk of patient infection and discomfort from invasive sampling methods and erroneous test results due to time delays between when the blood is drawn and analyzed.
"This portfolio will provide the purchaser with the coverage necessary to develop next generation monitoring devices," said Dean Becker, ICAP Ocean Tomo CEO. This portfolio should be of interest to any entity involved in diabetes management or blood monitoring markets, or developing products for analyte measurement.
To learn more about the patents available for sale in this portfolio or how to sell or buy intellectual property please contact ICAP Ocean Tomo at 1-866-779-8363 or at [email protected].
About ICAP Ocean Tomo LLC
ICAP Ocean Tomo is the intellectual property brokerage division of ICAP.
ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP is also the source of global market information and research for professionals in the international financial markets. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.
SOURCE ICAP Ocean Tomo
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All